Research Summary

Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics. He is a core faculty member with the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), located in the Department of Clinical Pharmacy.

Jeroen has worked on research to understand the clinical and economic value of healthcare interventions. His research has frequently been conducted in the context of health technology assessment (HTA), with a focus on comparative effectiveness and cost-effectiveness. Prompted by the challenges encountered in applied research projects, Jeroen has performed methodological research. Notable contributions are the development of novel statistical methods to overcome the typical challenges in model-based cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. Furthermore, Jeroen led initiatives to develop guidance for consumers and producers of network meta-analysis studies. He has promoted a more transparent and credible approach to model-based health economic evaluations and led the development of open-source simulation models to illustrate its feasibility. Jeroen has been involved in the ongoing development of an R software package to develop simulation models for health economic evaluations.

Jeroen’s current research interests are the clinical and economic value of precision medicine, incorporating health disparities in health economic modeling studies, and statistical methods for evidence synthesis.

Education

Faculty of Human Movement Sciences, Vrije Universiteit, Netherlands, MSc, 1998, Human Movement Sciences
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, MSc, 2001, Epidemiology
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, PhD, 2004, Epidemiology

Selected Publications

  1. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Mol Diagn Ther. 2024 09; 28(5):525-536.  View on PubMed
  2. Zhang I, Jansen JP, Yungher BJ, Kielhorn A, Yee KS. Commentary: Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front Immunol. 2024; 15:1403802.  View on PubMed
  3. Marshall DA, Hua N, Buchanan J, Christensen KD, Frederix GWJ, Goranitis I, Ijzerman M, Jansen JP, Lavelle TA, Regier DA, Smith HS, Ungar WJ, Weymann D, Wordsworth S, Phillips KA. Paving the path for implementation of clinical genomic sequencing globally: Are we ready? Health Aff Sch. 2024 May; 2(5):qxae053.  View on PubMed
  4. Maciel D, Jansen JP, Klijn SL, Towle K, Dhanda D, Malcolm B, Cope S. Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma. Value Health. 2024 Aug; 27(8):1012-1020.  View on PubMed
  5. Park JE, Campbell H, Towle K, Yuan Y, Jansen JP, Phillippo D, Cope S. Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data. Value Health. 2024 03; 27(3):278-286.  View on PubMed
  6. Jansen JP, Brewer IP, Chung S, Sullivan P, Espinosa OD, Grossman JP. The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics. Value Health. 2024 02; 27(2):143-152.  View on PubMed
  7. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv. 2023 Oct 28.  View on PubMed
  8. Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value Health. 2023 12; 26(12):1697-1710.  View on PubMed
  9. Jansen JP, Incerti D, Trikalinos TA. Multi-state network meta-analysis of progression and survival data. Stat Med. 2023 08 30; 42(19):3371-3391.  View on PubMed
  10. Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. J Comp Eff Res. 2023 05; 12(5):e220098.  View on PubMed
  11. Cope S, Chan K, Campbell H, Chen J, Borrill J, May JR, Malcolm W, Branchoux S, Kupas K, Jansen JP. A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma. Value Health. 2023 04; 26(4):465-476.  View on PubMed
  12. Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, Zheng Y, Snider JT, Locke FL. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022 12; 63(13):3052-3062.  View on PubMed
  13. Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Med Decis Making. 2022 10; 42(7):906-922.  View on PubMed
  14. Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 05; 40(5):489-495.  View on PubMed
  15. Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, Mullins CD, Willke RJ, Orsini LS. Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med. 2021 12 06; 19(1):307.  View on PubMed
  16. Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021 10; 62(10):2482-2491.  View on PubMed
  17. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R. . Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clinical Kidney Journal. 2021; 4(14):1136-46.  View on PubMed
  18. Jones KM, Cook-Deegan R, Rotimi CN, Callier SL, Bentley AR, Stevens H, Phillips KA, Jansen JP, Weyant CF, Roberts DE, Zielinski D, Erlich Y, Garrison NA, Carroll SR, Ossorio PN, Moreau Y, Wang M. Complicated legacies: The human genome at 20. Science. 2021 02 05; 371(6529):564-569.  View on PubMed
  19. Popoff E, Besada M, Jansen JP, Cope S, Kanters S. Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews. Syst Rev. 2020 Dec 13; 9(1):293.  View on PubMed
  20. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020 12; 9(18):1275-1284.  View on PubMed

Go to UCSF Profiles, powered by CTSI